Fate Historical Income Statement
| FATE Stock | USD 3.17 0.49 18.28% |
Historical analysis of Fate Therapeutics income statement accounts such as Selling General Administrative of 85.5 M or Total Revenue of 66.7 M can show how well Fate Therapeutics performed in making a profits. Evaluating Fate Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Fate Therapeutics's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Fate Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Fate Therapeutics is a good buy for the upcoming year.
Fate |
About Fate Income Statement Analysis
Fate Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Fate Therapeutics shareholders. The income statement also shows Fate investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Fate Therapeutics Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Fate Therapeutics. It is also known as Fate Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Cost Of Revenue
Cost of Revenue is found on Fate Therapeutics income statement and represents the costs associated with goods and services Fate Therapeutics provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Income Before Tax
Income Before Tax which can also be referred as pre-tax income is reported on Fate Therapeutics income statement and is an important metric when analyzing Fate Therapeutics profitability. Accounting techniques because taxes can be complex, and not perfectly consistent from one company to company, an analyst may use pre-tax income as a more stable measure of profitability.Most accounts from Fate Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Fate Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fate Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For information on how to trade Fate Stock refer to our How to Trade Fate Stock guide.At present, Fate Therapeutics' Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Selling General Administrative is expected to grow to about 85.5 M, whereas Operating Income is projected to grow to (181 M).
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 4.5M | 5.8M | 6.7M | 7.1M | Depreciation And Amortization | 5.9M | 13.8M | 18.3M | 19.2M |
Fate Therapeutics income statement Correlations
Click cells to compare fundamentals
Fate Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Fate Therapeutics income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 4.3M | 3.1M | 5.9M | 13.8M | 18.3M | 19.2M | |
| Interest Expense | 1.8M | 2.4M | 4.5M | 5.8M | 6.7M | 7.1M | |
| Selling General Administrative | 23.6M | 33.9M | 57.3M | 84.2M | 81.4M | 85.5M | |
| Total Revenue | 10.7M | 31.4M | 55.8M | 96.3M | 63.5M | 66.7M | |
| Gross Profit | (77.1M) | (94.2M) | 50.0M | 96.3M | (98.2M) | (93.3M) | |
| Other Operating Expenses | 111.4M | 159.5M | 272.8M | 404.7M | 254.0M | 266.7M | |
| Operating Income | (100.7M) | (128.1M) | (217.0M) | (308.4M) | (190.5M) | (181.0M) | |
| Ebit | (100.7M) | (128.1M) | (217.0M) | (308.4M) | (190.5M) | (181.0M) | |
| Research Development | 87.8M | 125.6M | 215.5M | 320.5M | 172.6M | 93.8M | |
| Ebitda | (96.4M) | (125.0M) | (211.1M) | (294.6M) | (172.2M) | (163.6M) | |
| Cost Of Revenue | 87.8M | 125.6M | 5.9M | 13.8M | 161.7M | 169.8M | |
| Total Operating Expenses | 111.4M | 159.5M | 272.8M | 404.7M | 254.0M | 266.7M | |
| Income Before Tax | (98.1M) | (173.4M) | (212.2M) | (281.7M) | (160.9M) | (152.9M) | |
| Total Other Income Expense Net | 2.6M | (45.3M) | 4.8M | 26.7M | 29.6M | 31.1M | |
| Net Income | (97.7M) | (170.3M) | (206.3M) | (255.1M) | (160.9M) | (152.9M) | |
| Income Tax Expense | (441K) | (3.1M) | (5.9M) | (26.7M) | 18.1M | 19.0M | |
| Net Income From Continuing Ops | (98.1M) | (173.4M) | (212.2M) | (281.7M) | (173.2M) | (164.5M) | |
| Non Operating Income Net Other | 494K | 2.6M | (45.3M) | 4.8M | 4.4M | 4.6M | |
| Net Income Applicable To Common Shares | (98.1M) | (173.4M) | (212.2M) | (281.7M) | (253.5M) | (240.9M) | |
| Interest Income | 4.3M | 2.4M | 1.3M | 5.8M | 15.7M | 16.4M | |
| Net Interest Income | 2.6M | 2.4M | 1.3M | 5.8M | 15.7M | 16.4M | |
| Reconciled Depreciation | 2.2M | 3.1M | 5.9M | 13.8M | 18.2M | 19.2M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Fate Therapeutics is a strong investment it is important to analyze Fate Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Fate Therapeutics' future performance. For an informed investment choice regarding Fate Stock, refer to the following important reports:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fate Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For information on how to trade Fate Stock refer to our How to Trade Fate Stock guide.You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fate Therapeutics. If investors know Fate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fate Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.64) | Revenue Per Share 0.123 | Quarterly Revenue Growth 0.581 | Return On Assets (0.22) | Return On Equity (0.47) |
The market value of Fate Therapeutics is measured differently than its book value, which is the value of Fate that is recorded on the company's balance sheet. Investors also form their own opinion of Fate Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Fate Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fate Therapeutics' market value can be influenced by many factors that don't directly affect Fate Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fate Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fate Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fate Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.